Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 2/20 | 0.32 |
| ▸ | NCF1 | P14598 | 2/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22014790 | 0.89 | PAOX (0.41) | ALOX15PAOXCA2CA1CA9 | |
| SCHEMBL13485582 | 0.87 | PAOX (0.39) | PAOXCA2CA1CA9HTR7 | |
| SCHEMBL22014792 | 0.82 | KEAP1 (0.39) | ALOX15ACE2LOX | |
| SCHEMBL18803169 | 0.81 | PAOX (0.38) | PAOXCA2CA1CA9HTR7 | |
| SCHEMBL22779960 | 0.81 | ALOX15 (0.33) | ALOX15 | |
| SCHEMBL14157926 | 0.80 | PAOX (0.35) | PAOXCA2CA1CA9HTR7 | |
| SCHEMBL4564530 | 0.77 | PAOX (0.47) | PAOXHTR7 | |
| SCHEMBL17102198 | 0.77 | CA2 (0.40) | ALOX15PAOXCA2CA1CA9 | |
| SCHEMBL12015831 | 0.74 | PAOX (0.39) | PAOXCA2CA1CA9LMNA | |
| SCHEMBL10067366 | 0.73 | PAOX (0.37) | PAOXCA2CA1CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | ALOX15 8/4885PAOX 35/4885CA2 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.